Better Buying Opportunity: Large-Cap or Small-Cap Stocks?
Markets slid after top economic advisor to the Trump Administration, Gary Cohn, resigned. This added to the concerns Wall Street already had on rising rates and the President's steel and aluminum tariffs. Lamar Villere, Portfolio Manager of the Villere Balanced Fund, was with us to discuss the state of the markets.
Trade war not good for business, but it's really bad for multi-national corporations. Villere added that small caps will be more shielded from a trade war because they are less exposed to international macroeconomic variables.
The portfolio manager said rising interest rates are a bigger risk for markets than the steel and aluminum tariffs. The reason is because it is too hard to predict how other countries will respond, Villere adds.
Villere is on ETF bubble watch, which he says is a crowded space. He warns that "you don't want to be in a crowded trade." He adds that these ETFs are not as diverse as people think.
It might not be what investors want to hear… but bringing down inflation could mean interest rates stay higher for (even) longer. But it's not all downside.
President Joe Biden and Chinese President Xi Jinping have discussed Taiwan, artificial intelligence and security issues in a call meant to demonstrate a return to regular leader-to-leader dialogue between the two powers.
April is Earth month, and while the green revolution might feel far away, the founder of climate VC Siam Capital says it’s on it’s way, and, even better: it won't cost you more.
From snow in April to heatwaves in December, it’s hard to plan a trip in a climate change world. Startup Sensible Weather thinks weather-based travel reimbursements are the solution.
Between corporate debt and the widening gap between ‘the haves and the have nots,’ there are reasons to be cautious about the economy, even with interest rate cuts on their way.
If the A.I. hype hasn’t given you enough of a reason to be excited (and a little terrified), the CEO of Zapata AI says the next frontier is designing bridges or creating pharmaceutical drugs.
